The effect of the GM-CSF/IL-3 fusion protein PIXY321 on bone marrow and circulating haemopoietic cells of previously untreated patients with cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/95698
Title:
The effect of the GM-CSF/IL-3 fusion protein PIXY321 on bone marrow and circulating haemopoietic cells of previously untreated patients with cancer.
Authors:
Gheilmini, Michele; Pettengell, Ruth; Coutinho, Lucia H; Testa, Nydia G; Crowther, Derek
Abstract:
This is a phase I/II study of the GM-CSF/IL-3 fusion protein (PIXY321. Patients were treated with PIXY321 at a daily subcutaneous dose of 500, 750 and 1000 micrograms/m2 for 14 d. Side-effects were mild and consisted mainly of injection-site reactions and constitutional symptoms. A biphasic modest increase of white blood count (2-5-fold) and platelets (1-1.5 fold) was seen, accompanied by an increased bone marrow cellularity and an increase in circulating progenitors. Colony-forming cells in the blood rose to a median of 184 granulocyte/macrophage-colony forming cells (GM-CFC)/ml, eight Mix-CFC/ml, 250 burst forming units-erythroid (BFU-E)/ml and 140 CFU-mega-karyocytes/ml, corresponding to a 10-, 2.5, 8- and 30-fold increase respectively. When seeded for long-term culture on irradiated bone marrow stroma, the mobilized cells were not able to sustain haemopoiesis in vitro to the same degree as bone marrow. Taken together these results indicate that PIXY321 has a biological effect in humans more similar to that of IL-3 than to that of GM-CSF.
Affiliation:
CRC Department of Medical Oncology, Christie Hospital, Manchester.
Citation:
The effect of the GM-CSF/IL-3 fusion protein PIXY321 on bone marrow and circulating haemopoietic cells of previously untreated patients with cancer. 1996, 93 (1):6-12 Br. J. Haematol.
Journal:
British Journal of Haematology
Issue Date:
Apr-1996
URI:
http://hdl.handle.net/10541/95698
DOI:
10.1046/j.1365-2141.1996.4731015.x
PubMed ID:
8611477
Type:
Article
Language:
en
ISSN:
0007-1048
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorGheilmini, Micheleen
dc.contributor.authorPettengell, Ruthen
dc.contributor.authorCoutinho, Lucia Hen
dc.contributor.authorTesta, Nydia Gen
dc.contributor.authorCrowther, Dereken
dc.date.accessioned2010-04-06T11:18:56Z-
dc.date.available2010-04-06T11:18:56Z-
dc.date.issued1996-04-
dc.identifier.citationThe effect of the GM-CSF/IL-3 fusion protein PIXY321 on bone marrow and circulating haemopoietic cells of previously untreated patients with cancer. 1996, 93 (1):6-12 Br. J. Haematol.en
dc.identifier.issn0007-1048-
dc.identifier.pmid8611477-
dc.identifier.doi10.1046/j.1365-2141.1996.4731015.x-
dc.identifier.urihttp://hdl.handle.net/10541/95698-
dc.description.abstractThis is a phase I/II study of the GM-CSF/IL-3 fusion protein (PIXY321. Patients were treated with PIXY321 at a daily subcutaneous dose of 500, 750 and 1000 micrograms/m2 for 14 d. Side-effects were mild and consisted mainly of injection-site reactions and constitutional symptoms. A biphasic modest increase of white blood count (2-5-fold) and platelets (1-1.5 fold) was seen, accompanied by an increased bone marrow cellularity and an increase in circulating progenitors. Colony-forming cells in the blood rose to a median of 184 granulocyte/macrophage-colony forming cells (GM-CFC)/ml, eight Mix-CFC/ml, 250 burst forming units-erythroid (BFU-E)/ml and 140 CFU-mega-karyocytes/ml, corresponding to a 10-, 2.5, 8- and 30-fold increase respectively. When seeded for long-term culture on irradiated bone marrow stroma, the mobilized cells were not able to sustain haemopoiesis in vitro to the same degree as bone marrow. Taken together these results indicate that PIXY321 has a biological effect in humans more similar to that of IL-3 than to that of GM-CSF.en
dc.language.isoenen
dc.subjectHaematopoietic Stem Cellsen
dc.subjectOvarian Canceren
dc.subject.meshAdult-
dc.subject.meshCell Count-
dc.subject.meshCell Movement-
dc.subject.meshFemale-
dc.subject.meshGranulocyte-Macrophage Colony-Stimulating Factor-
dc.subject.meshHematopoietic Stem Cells-
dc.subject.meshHodgkin Disease-
dc.subject.meshHumans-
dc.subject.meshInterleukin-3-
dc.subject.meshLeukocyte Count-
dc.subject.meshLymphoma-
dc.subject.meshLymphoma, Non-Hodgkin-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshOvarian Neoplasms-
dc.subject.meshPlatelet Count-
dc.subject.meshRecombinant Fusion Proteins-
dc.titleThe effect of the GM-CSF/IL-3 fusion protein PIXY321 on bone marrow and circulating haemopoietic cells of previously untreated patients with cancer.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital, Manchester.en
dc.identifier.journalBritish Journal of Haematologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.